The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China.
Int J Mol Sci. 2023 Jul 13;24(14):11387. doi: 10.3390/ijms241411387.
The intestinal flora plays an important role in the occurrence and development of liver cancer, affecting the efficacy and side effects of conventional antitumor therapy. Recently, immunotherapy for liver cancer has been a palliative treatment for patients with advanced liver cancer lacking surgical indications. Representative drugs include immune checkpoint inhibitors, regulators, tumor vaccines, and cellular immunotherapies. The effects of immunotherapy on liver cancer vary because of the heterogeneity of the tumors. Intestinal flora can affect the efficacy and side effects of immunotherapy for liver cancer by regulating host immunity. Therefore, applying probiotics, prebiotics, antibiotics, and fecal transplantation to interfere with the intestinal flora is expected to become an important means of assisting immunotherapy for liver cancer. This article reviews publications that discuss the relationship between intestinal flora and immunotherapy for liver cancer and further clarifies the potential relationship between intestinal flora and immunotherapy for liver cancer.
肠道菌群在肝癌的发生发展中起着重要作用,影响常规抗肿瘤治疗的疗效和副作用。近年来,肝癌的免疫治疗已成为缺乏手术指征的晚期肝癌患者的一种姑息治疗方法。代表性药物包括免疫检查点抑制剂、调节剂、肿瘤疫苗和细胞免疫疗法。由于肿瘤的异质性,免疫治疗对肝癌的疗效不同。肠道菌群可以通过调节宿主免疫来影响肝癌的免疫治疗效果和副作用。因此,应用益生菌、益生元、抗生素和粪便移植来干扰肠道菌群有望成为辅助肝癌免疫治疗的重要手段。本文综述了讨论肠道菌群与肝癌免疫治疗关系的出版物,并进一步阐明了肠道菌群与肝癌免疫治疗之间的潜在关系。